NASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Price, News & Analysis $4.19 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.18 -0.02 (-0.36%) As of 06/18/2026 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Treace Medical Concepts Stock (NASDAQ:TMCI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TMCI alerts:Sign Up Key Stats Today's Range$4.05▼$4.3850-Day Range$1.53▼$4.2352-Week Range$1.17▼$7.78Volume1.45 million shsAverage Volume678,259 shsMarket Capitalization$271.81 millionP/E RatioN/ADividend YieldN/APrice Target$4.77Consensus RatingReduce Company Overview Treace Medical Concepts, Inc. is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates. The Lapiplasty System has received clearance from the U.S. Food and Drug Administration and is supported by clinical evidence demonstrating its effectiveness for patients with moderate to severe bunion deformities. Treace works closely with a network of foot and ankle surgeons, offering hands-on training programs and educational resources to facilitate proper adoption of its technology in hospital and ambulatory surgery center settings. In addition to bunion correction, the company continues to explore adjacent applications in foot and ankle reconstruction. Founded in 2017 and headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts initially built its commercial presence in North America and is evaluating opportunities for international expansion. The company’s management team brings together experienced medical device executives, orthopedic surgeons, and industry veterans committed to advancing the standard of care in foot and ankle surgery. Treace continues to invest in research and development as it seeks to broaden its product portfolio and drive long-term growth in the orthopedic market.AI Generated. May Contain Errors. Read More Treace Medical Concepts Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreTMCI MarketRank™: Treace Medical Concepts scored higher than 41% of companies evaluated by MarketBeat, and ranked 583rd out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingReduce Consensus RatingTreace Medical Concepts has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 2 sell ratings.Upside PotentialTreace Medical Concepts has a consensus price target of $4.77, representing about 13.8% upside from its current price of $4.19.Amount of Analyst CoverageTreace Medical Concepts has only been the subject of 1 research reports in the past 90 days.Read more about Treace Medical Concepts' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Treace Medical Concepts are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -4.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -4.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Treace Medical Concepts' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.27% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 7.34.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 13.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.96 News SentimentTreace Medical Concepts has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.Search Interest2 people have searched for TMCI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,104,801.00 in company stock, which represents 0.4065% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,104,801.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.42% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Treace Medical Concepts' insider trading history. Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TMCI Stock News HeadlinesTreace Medical Concepts (NASDAQ:TMCI) Rating Increased to Hold at Wall Street ZenJune 20 at 1:30 AM | americanbankingnews.comTreace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant SystemJune 18 at 7:05 AM | globenewswire.comThe Next QualcommPorter Stansberry recommended Qualcomm in 1999 at $4 a share - it climbed more than 5,000%. He found the same tollbooth dynamic in Shopify in 2016, which has risen over 3,500% since. Now he believes he has found his third: a structurally irreplaceable company at the center of a multitrillion-dollar national security buildout backed by more than $3 trillion in public and private capital. A key event this year could accelerate the move. He has also identified four additional stocks positioned to climb before most investors catch on.June 20 at 1:00 AM | Porter & Company (Ad)Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 22,887 SharesJune 12, 2026 | insidertrades.comTreace to Present at the Sidoti Small Cap ConferenceJune 11, 2026 | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 50,000 SharesJune 2, 2026 | insidertrades.comTreace Medical Concepts Balances Growth With Earnings StrainJune 1, 2026 | tipranks.comJohn Treace Purchases 4,508 Shares of Treace Medical Concepts (NASDAQ:TMCI) StockMay 29, 2026 | insidertrades.comSee More Headlines TMCI Stock Analysis - Frequently Asked Questions How have TMCI shares performed this year? Treace Medical Concepts' stock was trading at $2.45 at the beginning of the year. Since then, TMCI shares have increased by 71.0% and is now trading at $4.19. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings results on Friday, May, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. The business earned $47.20 million during the quarter, compared to analyst estimates of $45.96 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 67.04% and a negative net margin of 29.44%. Read the conference call transcript. When did Treace Medical Concepts IPO? Treace Medical Concepts (TMCI) raised $180 million in an IPO on Thursday, April 22nd 2021. The company issued 11,250,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Top institutional shareholders of Treace Medical Concepts include Bank of America Corp DE (4.95%), Renaissance Technologies LLC (0.81%), Dimensional Fund Advisors LP (0.30%) and State of Wyoming (0.15%). Insiders that own company stock include John T Treace, James T Treace, Richard W Mott, Sean F Scanlan and Deepti Jain. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Treace Medical Concepts own? Based on aggregate information from My MarketBeat watchlists, some other companies that Treace Medical Concepts investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/08/2026Today6/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 TMCI's financial health is in the Green zone, according to TradeSmith. TMCI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMCI CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Price Target for Treace Medical Concepts$4.77 High Price Target$7.00 Low Price Target$3.00 Potential Upside/Downside+13.8%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59 million Net Margins-29.44% Pretax Margin-29.44% Return on Equity-67.04% Return on Assets-30.28% Debt Debt-to-Equity Ratio0.72 Current Ratio3.58 Quick Ratio2.53 Sales & Book Value Annual Sales$212.69 million Price / Sales1.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book3.06Miscellaneous Outstanding Shares64,870,000Free Float49,680,000Market Cap$271.81 million OptionableOptionable Beta1.40 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TMCI) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBofA: Digital Dollar Coming 2025-2030The US government has ONLY ONE mathematical escape from $38.4T in debt: explosive AI-driven GDP growth. AI ...Decentralized Masters | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Treace Medical Concepts With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
